These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33377439)

  • 1. Use of real-world evidence in economic assessments of pharmaceuticals in the United States.
    Lee W; Dayer V; Jiao B; Carlson JJ; Devine B; Veenstra DL
    J Manag Care Spec Pharm; 2021 Jan; 27(1):5-14. PubMed ID: 33377439
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
    Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
    [No Abstract]   [Full Text] [Related]  

  • 3. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
    Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 5. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
    Hung A; Mullins CD; Slejko JF; Haines ST; Shaya F; Lugo A
    J Manag Care Spec Pharm; 2019 Mar; 25(3):342-349. PubMed ID: 30816818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
    Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
    J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
    [No Abstract]   [Full Text] [Related]  

  • 7. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
    Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
    J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
    Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
    J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
    Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment.
    Dhanda DS; Veenstra DL; Regier DA; Basu A; Carlson JJ
    J Manag Care Spec Pharm; 2020 Apr; 26(4):529-537. PubMed ID: 32223606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of real-world evidence in meta-analyses and cost-effectiveness models.
    Bowrin K; Briere JB; Levy P; Toumi M; Millier A
    J Med Econ; 2020 Oct; 23(10):1053-1060. PubMed ID: 32657189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned.
    Hung A; Lugo A; Mullins CD
    J Manag Care Spec Pharm; 2019 Aug; 25(8):922-926. PubMed ID: 31347978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 16. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review.
    Yu JS; Chin L; Oh J; Farias J
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1028-1040. PubMed ID: 28944733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
    Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
    [No Abstract]   [Full Text] [Related]  

  • 19. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
    Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
    [No Abstract]   [Full Text] [Related]  

  • 20. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.